Reversible Cerebral Vasoconstriction Syndrome With Concomitant Transient Global Amnesia

Brief Title

Reversible Cerebral Vasoconstriction Syndrome With Concomitant Transient Global Amnesia

Official Title

Reversible Cerebral Vasoconstriction Syndrome With Concomitant Transient Global Amnesia : a Serie of 3 Cases Report

Brief Summary

      Reversible cerebral vasoconstriction syndrome (RCVS) is characterized by severe, unusual
      headaches associated with multifocal segmental vasoconstriction of the intracerebral
      arteries. In addition to headache, focal neurological deficit and/or seizures are quite
      frequently described, but anterograde amnesia seems to but extremely rare. Indeed, to date,
      only one case of RCVS associated with transient global amnesia (TGA) has been published. In
      case of an atypical presentation of TG, associated with brutal headaches, it is important not
      to ignore an assocation with RCVS because management, treatment, evolution and prognosis are
      different. Indeed, TGA is a monophasic phenomenon of less than 24 hours duration, without
      associated complications, which does not require any particular treatment. On the other hand,
      RCVS, although most often of excellent prognosis, can have severe complications such as
      intracerebral hemorrhage, subarachnoid hemorrhage, posterior reversible encephalopathy
      syndrome and cerebral infarction. In order to limit headaches and potential complications,
      RCVS require special management, including symptomatic treatments for headaches, complete
      rest, removal of precipitin factors and introduction of calcium channel blockers for a few

      This study aim to described three cases of patient who presented with concomitant TGA and
      RCVS, and to discuss pathogenic mechanism which may be similar in both these pathologies.

Study Type


Primary Outcome

Occurrence of concomitant TGA and proven RCVS


Transient Global Amnesia


* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Estimated Enrollment


Start Date

January 1, 2012

Completion Date

November 8, 2018

Primary Completion Date

November 8, 2018

Eligibility Criteria

        Inclusion Criteria:

          -  Patients with a proven or probable RCVS concomitant with certain transient global

        Exclusion Criteria:

          -  Not proven transient global amnesia, not proven or possible RCVS




18 Years - N/A

Accepts Healthy Volunteers



Nicolas Gaillard, MD, , 

Location Countries


Location Countries


Administrative Informations



Organization ID


Responsible Party


Study Sponsor

University Hospital, Montpellier

Study Sponsor

Nicolas Gaillard, MD, Principal Investigator, University Hospital, Montpellier

Verification Date

November 2018